[{"id":"7ef4af00-eb0b-4c60-9128-d93df5188777","acronym":"","url":"https://clinicaltrials.gov/study/NCT04214392","created_at":"2021-01-18T20:31:17.890Z","updated_at":"2024-07-02T16:35:14.015Z","phase":"Phase 1","brief_title":"Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma","source_id_and_acronym":"NCT04214392","lead_sponsor":"City of Hope Medical Center","biomarkers":" MMP2","pipe":" | ","alterations":" MMP2-H","tags":["MMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MMP2-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHM 1101"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-19"},{"id":"c3b4433b-bed2-433c-ac5b-3eebb0048cd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627323","created_at":"2022-11-25T15:58:16.470Z","updated_at":"2024-07-02T16:35:29.405Z","phase":"Phase 1","brief_title":"CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma","source_id_and_acronym":"NCT05627323","lead_sponsor":"Chimeric Therapeutics","biomarkers":" MMP2","pipe":" | ","alterations":" IDH wild-type","tags":["MMP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHM 1101"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2041","study_completion_date":" 01/01/2041","last_update_posted":"2023-11-13"}]